The Psychedelic Frontier: A Cross-Specialty Review of Healthcare Providers' Attitudes on Psychedelic-Assisted Therapy in the US
DOI:
https://doi.org/10.18192/uojm.v15i2.7456Keywords:
Healthcare Provider Attitudes, Psychedelics, Psychedelic-Assisted Therapy, PAT, PsychotherapyAbstract
Psychedelics, historically used for transcendent experiences, have garnered renewed interest for their potential therapeutic applications, particularly in treating mental health conditions such as depression, PTSD, and addiction. Despite initial enthusiasm in the mid-20th century, the War on Drugs led to a decades-long hiatus in research. However, recent studies have demonstrated promising clinical outcomes, reigniting interest in integrating psychedelic-assisted therapy (PAT) into modern medical practice. This review examines healthcare professionals’ attitudes toward psychedelic-assisted therapy (PAT), exploring how these attitudes vary across specialties. A systematic literature review of 11 relevant articles, drawn from PubMed, Medline OVID, and EMBASE, assessed U.S. healthcare professionals' perceptions of PAT, focusing on attitudes, concerns, and factors influencing factors. Healthcare professionals expressed cautiously favorable attitudes toward PAT, supporting further research and education, while concerns centered on potential psychiatric and neurocognitive risks, addiction relapse, and a lack of trained providers. Concerns were primarily centered on psychiatric and neurocognitive risks, addiction relapse, and the shortage of trained providers. The review also highlighted the importance of increasing awareness, training, and education in psychedelic medicine, with guidelines from the American Psychedelic Practitioners Association (APPA) emphasizing licensure and continued professional development. Despite some limitations, including an overrepresentation of psychiatrists and psychologists in the literature, this review underscores the importance of interdisciplinary collaboration and further research to facilitate PAT’s integration into clinical practice.
----------
Les psychédéliques, historiquement utilisés pour des expériences transcendantes, suscitent un regain d’intérêt en raison de leurs applications thérapeutiques potentielles, en particulier dans le traitement de troubles mentaux tels que la dépression, le syndrome de stress post-traumatique et la toxicomanie. Malgré l’enthousiasme initial au milieu du 20e siècle, la guerre contre la drogue a entraîné une interruption de plusieurs décennies dans la recherche. Cependant, des études récentes ont démontré des résultats cliniques prometteurs, ravivant l’intérêt pour l’intégration de la psychothérapie assistée par psychédéliques (PAP) dans la pratique médicale moderne. Cette revue examine les attitudes des professionnels de santé à l’égard de la PAP, en explorant comment ces attitudes varient selon les professions. Une revue systématique de la littérature portant sur 11 articles pertinents, tirés de PubMed, Medline OVID et EMBASE, a évalué la perception des professionnels de santé américains à l’égard de la PAP, en se concentrant sur leurs attitudes et leurs préoccupations. Les professionnels de santé ont exprimé des attitudes favorables mais prudentes à l’égard de la PAP, soutenant la poursuite de la recherche et de l’éducation, tout en exprimant des préoccupations centrées sur les risques psychiatriques et neurocognitifs potentiels, la rechute de la dépendance et le manque de prestataires formés. La revue a également souligné l’importance de sensibiliser, de former et d’éduquer davantage dans le domaine de la médecine psychédélique, avec des directives de l’American Psychedelic Practitioners Association (APPA) mettant l’accent sur l’octroi de licences et le développement professionnel continu. Malgré certaines limites, notamment une surreprésentation des psychiatres et des psychologues dans la littérature, cette revue souligne l’importance de la collaboration interdisciplinaire et de la poursuite des recherches pour faciliter l’intégration de la PAP dans la pratique clinique.
References
1. Nichols DE. Psychedelics. Pharmacol Rev. 2016 Apr;68(2):264–355.
2. King IV F. 02. The Mechanisms and Effects of Psychedelics [Internet]. Psychopharmacology Institute; 2024 Sep 1 [cited 2025 June 11]. Available from: https://psychopharmacologyinstitute.com/section/the-mechanisms-and-effects-of-psychedelics-2813-5748.
3. Carhart-Harris RL, Friston KJ. REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacol Rev. 2019 Jul;71(3):316–44.
4. Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH. Mitigation of post‐traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence. Drug Test Anal. 2012 Jul 26;4(7–8):649–59.
5. Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. RETRACTED ARTICLE: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019 Sep 1;236(9):2735–45.
6. Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 2019 Mar;101(5):774–8.
7. Gobbi G. The psychopharmacology of psychedelics: where the brain meets spirituality (CCNP Innovations in Neuropsychopharmacology Award). J Psychiatry Neurosci. 2024 Sep 19;49(5):E301–18.
8. Doblin RE, Christiansen M, Jerome L, Burge B. The Past and Future of Psychedelic Science: An Introduction to This Issue. J Psychoactive Drugs. 2019 Mar 15;51(2):93–7.
9. Hofmann A. LSD — My Problem Child. McGraw-Hill; 1979.
10. Grinspoon L, Bakalar JB. Psychedelic Drugs Reconsidered. 3rd ed. New York: The Lindesmith Center; 1997
11. Dyck E. LSD: a new treatment emerging from the past. CMAJ. 2015 Oct 6;187(14):1079–80.
12. Carhart-Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. 2017 May 10;42(11):2105–13.
13. Cohen A, Vakharia SP, Netherland J, Frederique K. How the war on drugs impacts social determinants of health beyond the criminal legal system. Ann Med. 2022 Jul 19;54(1):2024–38.
14. Stone BM. The War on Drugs has Unduly Biased Substance Use Research. Psychol Rep. 2022 Dec 20;127(4):2087–94.
15. Vahratian A, Blumberg SJ, Terlizzi EP, Schiller JS. Symptoms of Anxiety or Depressive Disorder and Use of Mental Health Care Among Adults During the COVID-19 Pandemic — United States, August 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):490–4.
16. George DR, Hanson R, Wilkinson D, Garcia-Romeu A. Ancient Roots of Today’s Emerging Renaissance in Psychedelic Medicine. Cult Med Psychiatry. 2022 Sep 2;46(4):890–903.
17. Rosenbaum D, Boyle AB, Rosenblum AM, Ziai S, Chasen MR, Med) Mp. Psychedelics for psychological and existential distress in palliative and cancer care. Curr Oncol. 2019 Aug 1;26(4):225–6.
18. Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. J Psychoactive Drugs. 2020 Aug 7;52(4):289–99.
19. Bird CIV, Modlin NL, Rucker JJH. Psilocybin and MDMA for the treatment of trauma-related psychopathology. Int Rev Psychiatry. 2021 Apr 3;33(3):229–49.
20. Nutt D. Psychedelic drugs—a new era in psychiatry? Dialogues Clin Neurosci. 2019 Jun 30;21(2):139–47.
21. Kelly JR, Clarke G, Harkin A, Corr SC, Galvin S, Pradeep V, et al. Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. Int J Clin Health Psychol. 2022 Dec 14;23(2):100349.
22. Barta S, Brooker J, O’Callaghan C. Health Care Workers’ Attitudes Toward and Knowledge of the Clinical Application of Classic Psychedelics for People with Serious Illness: A Systematic Review. J Palliat Med. 2024 Dec 4;0(0):1-14.
23. Davis AK, Agin-Liebes G, España M, Pilecki B, Luoma J. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. J Psychoactive Drugs. 2021 Sep 1;54(4):309–18.
24. Kim A, Suzuki J. Addiction specialists’ attitudes toward psychedelics: A National Survey. Am J Addict. 2023 Aug 7;32(6):606–9.
25. Kucsera A, Suppes T, Haug NA. Psychologists’ and psychotherapists’ knowledge, attitudes, and clinical practices regarding the therapeutic use of psychedelics. Clin Psychology and Psychoth. 2023 Jul 2;30(6):1369–79.
26. Hearn BG, Brubaker MD, Richardson G. Counselors’ attitudes toward psychedelics and their use in therapy. J Couns Dev. 2022 Mar 19;100(4):364–73.
27. Wang E, Mathai DS, Gukasyan N, Nayak S, Garcia-Romeu A. Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Sci Rep. 2024 Nov 14;14(1):28022.
28. Niles H, Fogg C, Kelmendi B, Lazenby M. Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliat Care. 2021 Dec 20;20(1):191.
29. Wells A, Fernandes M, Reynolds L. Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review. J Psychedelic Stud. 2024 Apr 10;8(1):43–62.
30. Reynolds LM, Barnett B, Weleff J, Morunga E, Wells A, Stack A, et al. The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. Palliat Support Care. 2022 Nov 3;22(4):664–73.
31. Szpak V, Kim A, Sager Z, Suzuki J. Survey of Massachusetts peer recovery coaches’ attitudes toward the use of psychedelics to treat substance use disorders. Addict Sci Clin Pract. 2024 Nov 25;19(1):86.
32. Sims EN, Holzworth J. Social Worker Attitudes towards Psychedelics. Clin Soc Work J. 2025 Feb 6;53(1):1–11.
33. Gopal DP, Chetty U, O’Donnell P, Gajria C, Blackadder-Weinstein J. Implicit bias in healthcare: clinical practice, research and decision making. Future Healthc J. 2021 Mar 29;8(1):40–8.
34. Perng W, Dhaliwal SK. Anti-Asian Racism and COVID-19: How It Started, How It Is Going, and What We Can Do. Epidemiology. 2022 May 1;33(3):379-82.
35. Ertorer SE. Racism and Mental Health: Examining the Psychological Toll of Anti-Asian Racism during the COVID-19 Pandemic. Genealogy. 2024 Aug 2;8(3):98.
36. Feher, Orsolya. Psychedelics and the media in the Visegrad countries. J. Psychedelic Stud. 2018 Aug;2(2):1-11.
37. https://www.brainfutures.org [Internet]. Seattle: American Psychedelic Practitioners Association; c2025 [cited 2025 Feb 27]. Available from: https://www.brainfutures.org/wp-content/uploads/2023/08/Professional-Practice-Guidelines-for-Psychedelic-Assisted-Therapy-Aug-2023.pdf
38. Prueitt WL, Sloshower J. Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees. Acad Psychiatry. 2023 Feb 26;47(1):74–7.
39. Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, et al. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. Int J Mol Sci. 2023 Jan 10;24(2):1329.
40. Velit-Salazar MR, Shiroma PR, Cherian E. A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder. Brain Sci. 2024 Mar 3;14(3):248.
41. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers. Neuropsychopharmacology. 1998 Oct;19(4):241–51.
42. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol. 2001 Dec 12;16(8):589–98.
43. Dumont GJH, Wezenberg E, Valkenberg MMGJ, De Jong CAJ, Buitelaar JK, Van Gerven JMA, et al. Acute neuropsychological effects of MDMA and ethanol (co-)administration in healthy volunteers. Psychopharmacology. 2008 Apr 28;197(3):465–74.
44. Van Wel JHP, Kuypers KPC, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG. Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors. Mendelson JE, editor. PLoS ONE. 2012 Jul 10;7(7):e40187.
45. Farré M, De La Torre R, Ó Mathúna B, Roset PN, Peiró AM, Torrens M, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology. 2004 Apr 8;173(3–4):364–75.
46. Dumont G, Van Hasselt J, De Kam M, Van Gerven J, Touw D, Buitelaar J, et al. Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers. J Psychopharmacol. 2011 Sep 3;25(4):478–89.
47. Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, et al. Dose-dependent Effects of Smoked Cannabis on Capsaicin-induced Pain and Hyperalgesia in Healthy Volunteers. Anesthesiology. 2007 Nov 1;107(5):785–96.
48. Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, et al. Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial. JAMA Netw Open. 2018 Nov 30;1(7):e184841.
49. Crean RD, Crane NA, Mason BJ. An Evidence Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive Functions. J Addict Med. 2011 Mar 1;5(1):1–8.
50. Lai MK, Tsang SW, Alder JT, Keene J, Hope T, Esiri MM, et al. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer’s disease. Psychopharmacology. 2004 Nov 18;179(3):673–7.
51. Yildirim B, Sahin SS, Gee A, Jauhar S, Rucker J, Salgado-Pineda P, et al. Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports. Psychol Med. 2024 Nov 20;54(15):1–13.
52. Preller KH, Vollenweider FX. Phenomenology, Structure, and Dynamic of Psychedelic States. In: Nichols DE, editor. Behavioral Neurobiology of Psychedelic Drugs. Heidelberg: Springer; 2016. p. 221–56.
53. Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology. 2011 Nov 20;25(11):1434–52.
54. Gardiner KM, Singleton JA, Sheridan J, Kyle GJ, Nissen LM. Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis – A systematic review. PLoS One. 2019 May 6;14(5):e0216556.
55. Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. American Journal of Psychiatry. 2017 Jul 1;174(7):695–6.
56. Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018 Jan;5(1):65–78.
57. Koffman R. Psychedelic-Assisted Therapy: Healing the “Wounds of War” [Internet]; 2024 Apr 9-11 [cited 2025 Jun 11]. Available from: https://www.socom.mil/care-coalition/SiteAssets/Conference-2024/Psychedelic%20Assisted%20Therapy%20Dr.%20Koffman.pdf?utm_source=chatgpt.com
58. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry. 2020 May 1;177(5):391–410.
59. Kraiem, E., Diener, M., Guss, J., Mavrides, L., & Saban, S. Psychoanalyst attitudes towards psychedelic-assisted therapy. Drugs: Education, Prevention and Policy. 2024 June 4:1–12.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Stefan Sampy, Rohan Sampy

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
- Authors publishing in the UOJM retain copyright of their articles, including all the drafts and the final published version in the journal.
- While UOJM does not retain any rights to the articles submitted, by agreeing to publish in UOJM, authors are granting the journal right of first publication and distribution rights of their articles.
- Authors are free to submit their works to other publications, including journals, institutional repositories or books, with an acknowledgment of its initial publication in UOJM.
- Copies of UOJM are distributed both in print and online, and all materials will be publicly available online. The journal holds no legal responsibility as to how these materials will be used by the public.
- Please ensure that all authors, co-authors and investigators have read and agree to these terms.
- Works are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.